Your search for bevacizumab returned 23 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Drugs in the Pipeline remove

Your search for bevacizumab returned 23 results

Sort Results:

Relevant Recent
Drugs in the Pipeline

Priority Review, sBLA Granted for Cervical Cancer Tx

The FDA has accepted Genentech's supplemental Biologics License Application (sBLA) and granted Priority Review for Avastin (bevacizumab) plus chemotherapy for the treatment of women with persistent, recurrent or metastatic cervical cancer.
Drugs in the Pipeline

Brain Cancer Vaccine Shows Promise in Phase 2 Trial

The use of Prophage Series G-100 (HSPPC-96; Agenus) in combination with current standard of care (radiation and temozolomide) demonstrates improvement in progression free survival in patients with newly diagnosed glioblastoma multiforme (GBM).
Drugs in the Pipeline

Phase 3 Results Announced for Neulasta in Colorectal Cancer

Amgen announced the results from a Phase 3 study, Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES) which evaluated Neulasta (pegfilgrastim) for the first-line treatment of locally-advanced or metastatic colorectal cancer.
Drugs in the Pipeline

Phase 3 Trial Update of Alimta for Nonsquamous Non-Small Cell Lung Cancer

Eli Lilly and Company announced today that the Phase 3 POINTBREAK trial did not meet its primary endpoint of improved overall survival for patients with nonsquamous non-small cell lung cancer (NSCLC) who were randomized to receive a combination of Alimta (pemetrexed for injection) with bevacizumab (Avastin; Genentech) and carboplatin induction followed by Alimta plus bevacizumab maintenance-the Alimta arm-compared to the combination of paclitaxel (Taxol; Bristol-Myers Squibb) with bevacizumab and carboplatin followed by bevacizumab maintenance-the paclitaxel arm.
Drugs in the Pipeline

Phase 3 study of Avastin for the treatment of ovarian cancer

Genentech announced results from its Phase 3 study of Avastin (bevacizumab) in combination with chemotherapy (carboplatin and gemcitabine) for the treatment of previously treated (recurrent), platinum-sensitive ovarian cancer.